CTLA-4 was highly expressed by tumour-infiltrating Treg cells in multiple models of transplantable syngeneic tumour cell lines of variable immunogenicity, as well as in human solid tumour subtypes including advanced melanoma, early-stage NSCLC, and renal cell cancer. Here, CTLA4 is linked to neoplasm.